These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25299876)

  • 21. Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings.
    Bastos ML; Campbell JR; Oxlade O; Adjobimey M; Trajman A; Ruslami R; Kim HJ; Baah JO; Toelle BG; Long R; Hoeppner V; Elwood K; Al-Jahdali H; Apriani L; Benedetti A; Schwartzman K; Menzies D
    Ann Intern Med; 2020 Aug; 173(3):169-178. PubMed ID: 32539440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of latent tuberculosis infection.
    Parekh MJ; Schluger NW
    Ther Adv Respir Dis; 2013 Dec; 7(6):351-6. PubMed ID: 24056289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
    Johnson KT; Churchyard GJ; Sohn H; Dowdy DW
    Clin Infect Dis; 2018 Sep; 67(7):1072-1078. PubMed ID: 29617965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Three months of once-weekly isoniazid plus rifapentine (3HP) in treating latent tuberculosis infection is feasible in patients with rheumatoid arthritis.
    Chen YM; Liao TL; Chen HH; Chen DY
    Ann Rheum Dis; 2018 Nov; 77(11):1688-1689. PubMed ID: 29674320
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of latent tuberculosis with 12 weeks isoniazid/rifapentine in clinical practice.
    Fröberg G; Jansson L; Bruchfeld J
    Eur Respir J; 2019 Feb; 53(2):. PubMed ID: 30409821
    [No Abstract]   [Full Text] [Related]  

  • 26. Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events.
    Lin SY; Chiu YW; Lu PL; Hwang SJ; Chen TC; Hsieh MH; Chen YH
    J Microbiol Immunol Infect; 2019 Feb; 52(1):158-162. PubMed ID: 29907535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates.
    Simkins J; Abbo LM; Camargo JF; Rosa R; Morris MI
    Transplantation; 2017 Jun; 101(6):1468-1472. PubMed ID: 27548035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Dec; 60(48):1650-3. PubMed ID: 22157884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin.
    Fluegge KR
    J Eval Clin Pract; 2014 Oct; 20(5):685-91. PubMed ID: 25087583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tuberculosis preventive chemotherapy: the times they are a-changin'.
    Dedicoat M; Lange C
    Int J Tuberc Lung Dis; 2015 Sep; 19(9):1002. PubMed ID: 26260815
    [No Abstract]   [Full Text] [Related]  

  • 31. Severe hypertension after initiation of rifapentine/isoniazid for latent tuberculosis in renal transplant candidates.
    Simkins J; Morris MI; Abbo LM; Camargo JF
    Transpl Int; 2017 Jan; 30(1):108-109. PubMed ID: 28032405
    [No Abstract]   [Full Text] [Related]  

  • 32. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
    Bliven-Sizemore EE; Sterling TR; Shang N; Benator D; Schwartzman K; Reves R; Drobeniuc J; Bock N; Villarino ME;
    Int J Tuberc Lung Dis; 2015 Sep; 19(9):1039-44, i-v. PubMed ID: 26260821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine.
    McClintock AH; Eastment M; McKinney CM; Pitney CL; Narita M; Park DR; Dhanireddy S; Molnar A
    BMC Infect Dis; 2017 Feb; 17(1):146. PubMed ID: 28196479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of latent tuberculosis infection: An update.
    Lobue P; Menzies D
    Respirology; 2010 May; 15(4):603-22. PubMed ID: 20409026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection.
    Pina JM; Clotet L; Ferrer A; Sala MR; Garrido P; Salleras L; Domínguez A
    Eur J Clin Microbiol Infect Dis; 2013 May; 32(5):647-55. PubMed ID: 23238684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of latent tuberculosis infection].
    Fraisse P;
    Rev Mal Respir; 2012 Apr; 29(4):579-600. PubMed ID: 22542415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis.
    Yu YY; Tsao SM; Yang WT; Huang WC; Lin CH; Chen WW; Yang SF; Chiou HL; Huang YW
    Int J Environ Res Public Health; 2019 Dec; 17(1):. PubMed ID: 31892222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
    Sterling TR; Moro RN; Borisov AS; Phillips E; Shepherd G; Adkinson NF; Weis S; Ho C; Villarino ME;
    Clin Infect Dis; 2015 Aug; 61(4):527-35. PubMed ID: 25904367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rifapentine and isoniazid for latent tuberculosis.
    Johnson JR
    N Engl J Med; 2012 Apr; 366(15):1447. PubMed ID: 22494127
    [No Abstract]   [Full Text] [Related]  

  • 40. Latent Mycobacterium tuberculosis infection.
    Getahun H; Matteelli A; Chaisson RE; Raviglione M
    N Engl J Med; 2015 May; 372(22):2127-35. PubMed ID: 26017823
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.